uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...
Why Shares of uniQure Are Up Thursday
The company announced a reorganization that included layoffs.
Why Shares of uniQure Are Dropping Tuesday
The company is facing being delisted from the S&P 600 Index.